| Research Grants: DEPARTMENT OF MEDICINE |
|
CARDIOLOGY
The grants received by department/division members are listed as follows: the members of the division, the title
of the project, the sponsor, and the $'s expended at the London Health Sciences Centre in the fiscal period.
- Almond D, Teefy P, Sridhar K. EPILOG - A clinical trial evaluating, 6 month clinical outcome following percutaneous
coronary intervention in patients treated with C7E3/fab bolus plus 12 hour infusion. Centocor Inc. $11600.
- Almond D, Teefy P, Sridhar K. TOSCA - A study of stents versus PTCA for occluded coronary arteries. A total
occulusion study of Canada. Johnson and Johnson. $2000.
- Almond D, Teefy P, Sridhar K. Coronary stent and delivery system for treatment of de novo and restenotic coronary
lesions. Cordis Corporation. $2500.
- Almond D, Teefy P, Sridhar K. ACS Multilink Coronary Stent - Cardiovascular advanced guidant. $4050.
- Almond D, Teefy P, Sridhar K, Kostuk W, Jablonksy G, Lucas A. BARD XT STENT STUDY. Interventional cardiology
clinical trials. Bard Canada. $4500.
- Almond D, Teefy P, Sridhar K. BARD ATHERECTOMY. X - tractor study. Bard Canada. $14400.
- Almond D, Teefy P, Sridhar K. PRIME. Efegratan versus heprin. Promotion of reperfusion by inhibition of thrombin
during myocardial infarction evolution (PRIME). Eli Lilly. $140000.
- Arnold M. CARE study: cholesterol and recurrent events. Bristol Myers Squibb. $66427.
- Arnold M. First-dose effects of capoten and generic captopril on blood pressure in patients with heart failure.
Bristol Myers Squibb. $25200.
- Arnold M. Comparison of spironolactone vs. placebo on mortality in patients with severe heart failure. Searle
Canada Inc. $10000.
- Arnold M. Study healing and early afterload reducing therapy. Hoechst-Roussel Canada. $9952.
- Arnold M. Evaluation of losartan in the elderly ( ELITE ). Merck Frosst Canada. $24600.
- Arnold M. Heart failure program. Merck Frosst Canada. $88425.
- Arnold M. HOPE (Heart Outcomes Prevention Evaluation). McMaster University. $24236.
- Arnold M, Feng Q. Modulators of in vivo npy responses in humans. Medical Research Council of Canada. $41141.
- Arnold M. Digoxin investigation group (DIG) study. Ottawa Civic Hospital. $10905.
- Arnold M. Arterial responsiveness in heart failure. Heart and Stroke Foundation of Ontario. $66619.
- Arnold M, Feng Q. Effects of smoking on vascular function and sympathetic responsiveness. Victoria Hospital
Research Institute. $5000.
- Arnold M. Arterial pressure pulses. Departmental Funds. $71810.
- Arnold M. Is prostacyclin, liberated by alpha-adrenoceptor stimulation, released from vascular endothelium
of vascular smooth muscle. LHSC Internal Research Fund. $7500.
- Boughner D. Three-dimensional color Doppler echocardiography. Heart and Stroke Foundation. $61025.
- Boughner D. Heart valve bioprostheses-biomaterials and biomechanics. Heart and Stroke Foundation of Ontario.
$105036.
- Boughner D, Fenster A, Pflugfelder P. Three-dimensional color Doppler echocardiography. Heart and Stroke Foundation
of Ontario. $33414.
- Chow L. Immunopathogenesis of graft vascular disease. Heart and Stroke Foundation. $65359.
- Chow L. Three-dimensional color Doppler echocardiography. LHSC Internal Research Fund. $6950.
- Chow L. Cellular immunity myocarditis. Medical Research Council of Canada. $21276.
- Chow L, Dekaban GA, Pickering JG. Gene therapy of allograft vascular disease. Multi-Organ Transplant Service.
$11250.
- Feng Q, Arnold M. L-arginine-nitric oxide pathway in heart failure. Heart and Stroke Foundation of Ontario.
$44828.
- Feng Q. L-Arginine transport in congestive heart failure. LHSC Internal Research Fund. $12500.
- Finnie K. Gusto study, global utilization of streptokinase and type for occluded coronary arteries. Genentech
Inc. $17124.
- Finnie K. A randomized placebo-controlled dose-finding study of lamifiban in patients with acute myocardial
infarction treated with either rt-pa aspirin and heparin or streptokinase and aspirin (PARADIGM). Hoffmann La Roche
Ltd. $2755.
- Finnie K. CAPRIE study. Sanofi Pharmaceutical Co. $83330.
- Klein G, Yee R. Ablation in atrial fibrillation. Heart and Stroke Foundation of Ontario. $87595.
- Massel D. Bedside Valsalva manoeuvre. Departmental Funds. $400.
- Pickering JG. Role of fibrillar collagens in the vascular response to injury. Medical Research Council. $44174.
- Pickering JG, Chan B. Role of B1 integrins in vascular remodeling. Heart and Stroke Foundation of Ontario.
$16679.
- Pickering JG. Vascular repair in transgenic mice expressing a collagen. Departmental Funds. $10400.
- Pickering G. Interplay between fibroblast growth factor-2 and fibrillar collagen in the control of vascular
smooth muscle cell migration. LHSC Internal Research Fund. $12500.
- Sharpe M, Kostuk W, Pfugfelder P, Brown J. Comparison of the efficacy and safety of inhaled nitricoxide to
nitroprusside in patients undergoing assessment for potential heart transplantation. University Hospital Pooled
Research Trust Fund. $6006.
- Sharpe M, Rylett R, Brown J, Watson B, Munoz D. Pathophysiology of prolonged paralysis following continuous
neuromuscular block. The Dr. R.A. Gordon Clinical Research Award. $20000.
- Teefy P. Collateral blood flow reserve in chronically occluded coronary arteries. Departmental Funds. $19159.
- Yee R. Nonpharmacologic treatments for atrial fibrillation. Heart and Stroke Foundation. $13418.
CLINICAL IMMUNOLOGY & ALLERGY
The grants received by department/division members are listed as follows: the members of the division in bold
type, the title of the project, the sponsor, and the $'s expended at the London Health Sciences Centre in the fiscal
period.
- Chodirker W. A study comparing the efficacy and safety of fexofenadine, and placebo in the treatment of perennial
allergic rhinitis. Marion Merrell Dow Canada. $15000.
- Mazza J. Comparison of fexofenadine versus loratadine in seasonal allergic rhinitis. Hoechst Marion Roussel
Canada. $2000.
- Mazza J, Moote W. A study comparing the efficacy and safety of fexofenadine and placebo in treatment of perennial
allergic rhinitis. Hoechst Marion Roussel Canada. $37965.
- Mazza J. A study of the safety and efficacy of ALLERVAX®. Nordic-Merrell. $86970.
- Mazza J, Moote W. A multi-centre, comparison of the safety and efficacy of Pranlukast with Claritin® in
patients with seasonal allergic rhinitis. Smithkline Beecham. $37050.
- Mazza J, Moote W. Does the addition of omeprazole to existing asthma treatment improve respiratory status in
patients with concurrent asthma and gastroesophageal reflux? Astra. $5400.
- Mazza J. A multi-centre, efficacy trial in subjects with asthma. Zeneca. $17777.
- Mazza J, Moote W. A multi-centre, parallel-group study to assess the clinical effect of beclomethasone in asthmatic
patients. Merck Frosst. $20710.
- Mazza J, Moote W. Efficacy and safety of mometasone furoate aqueous nasal spray in seasonal allergic rhinitis
patients. Schering. $26362.
- Moote W. A multi-centre, efficacy and safety of fluticasone propionate with budesonide via the turbuhaler in
adult patients with severe, reversible airways disease. Glaxo. $9550.
- Moote W. A study to determine the clinical equivalence between fluticasone propionate and fluticasone propionate
delivered via the metered-dose inhaler (MDI) in patients with moderate asthma. Glaxo. $1916.
- Toogood J. Effects of cumulative versus current dosage of budesonide on hypothalamic pituitary adrenal function
during eight years of ongoing asthma therapy. University of Western Ontario. Allergy Research Fund. $8743.
- Toogood J. Bone density in patients receiving long term inhaled steroid therapy for asthma. Astra/Draco. $6000.
- Toogood J. Evaluation of the efficacy and safety of the budesonide Turbuhaler for chronic asthma therapy. Astra
Pharma. $6000.
CLINICAL PHARMACOLOGY
The grants received by department/division members are listed as follows: the members of the division in bold
type, the title of the project, the sponsor, and the $'s expended at the London Health Sciences Centre in the fiscal
period.
- Bailey D, Freeman D, Bend J. Specific food
- constituent(s)interaction with drugs. Medical Research Council. $60000.
- Bailey D. Grapefruit juice-felodipine interaction:
- contribution of the bioflavonoid naringin.
- Department of Citrus State of Florida. $25000.
- Bailey D. Analysis of plasma diazepam and desmethyldiazepam concentrations in rhesus monkey. Ministry of Defense,
Canada. $17710.
- Bailey D. Analysis of plasma HI-6 concentrations and pharmacokinetics in man. Ministry of Defense, Canada.
$20000.
- Feldman R. Tyosine kinase-mediated sensitization of adenylyl cyclase activation: an application for a graduate
studentship award. LHSC Internal Research Fund. $12500.
- Feldman R, Hramiak I. Beta-adrenoceptor regulation in man. Medical Research Council of Canada. $78609.
- Feldman R, Arnold M. Insulin-mediated regulation of vasodilator mechanisms. Heart and Stroke Foundation of
Ontario. $75603.
- Feldman R, Karmazyn M. Effects of hydrogen peroxide on vascular and cardiac myocytes. Heart and Stroke Foundation
of Ontario. $30264.
- Feldman R. Regulation of vascular tone by tyrosine kinase activation: in Vivo and in Vitro studies. Departmental
Funds. $3400.
- Freeman D. Research Support. Multi-Organ Transplant Service and The Mutual Group, Masterman Lab. $164688.
- Freeman D, Oyewumi L, Rieder M. Predictive test for clozapine-induced agranulocytosis. Canadian Psychiatric
Research Foundation. $15000.
- Freeman D. Microsomal enzyme antibodies. University Hospital Pooled Research Trust Fund. $6500.
- Freeman D, Oyewumi K, Rieder M. In Vitro toxicity studies of neuroleptic drugs. University Hospital Pooled
Research Trust. $6500.
- Kreeft J. Alniditan in treatment of acute migraine. Role of fibrillar collagens in the vascular response to
injury. Janssen/Ortho. $10000.
- Zarnke K. Patient-directed management of essential hypertension using home blood pressure monitoring: a randomized
controlled trial. Bayer Inc. $107309.
- Zarnke K. The development and evaluation of different methods of information presentation to allow patients
to declare treatment preferences - Atrial fibrillation. Father Sean O'Sullivan Research Centre. $12500.
- Zarnke K. Is tobacco smoking associated with impaired insulin medicated vasodilatation? LHSC Internal Research
Fund. $12000.
CRITICAL CARE
The grants received by department/division members are listed as follows: the members of the division in bold
type, the title of the project, the sponsor, and the $'s expended at the London Health Sciences Centre in the fiscal
period.
- Chin-Yee, I, Doig G, Sibbald W, Martin CM. Diaspirin cross linked hemoglobin in an ovine model of sepsis. Baxter
Healthcare and URIF. $115219.
- Doig G, Sibbald W, Carruthers G, Anis A, Russell J. Development and evaluation of guidelines for the appropriate
use of antibiotics in the intensive care unit. Bayer Canada Inc. $76960.
- Doig G, Sibbald W, Martin C. Anti-cytokine therapy in an antibiotic treated peritonitis model of sepsis: dose
ranging study. Sandoz Pharmaceuticals Corp. $40771.
- Keenan S, Martin C, Chen L. Assessment and development of criteria for intensive care unit admission from the
emergency department in teaching and non-teaching hospitals. Victoria Hospital Research Development Fund. $10000.
- Keenan S, Block G, McCormack D, Dhawan R, Inman K. A randomized, controlled study of the use of noninvasive
positive pressure ventilation for patients developing respiratory failure within 48 hours of extubation. Respironics
Inc. $5000 US.
- Keenan S, McCormack D, Block G, Dhawan R, Inman K. The cost-effectiveness of non-invasive positive pressure
ventilation plus standard care, versus standard care alone, in patients admitted with an acute exacerbation of
chronic obstructive pulmonary disease. Respironics Inc. $101000.
- Martin C, Sibbald W. Studies on the effects of dopexamine on the microcirculation in sepsis. Speywood Laboratories.
$207000.
- Martin C. Transfusion requirements in critical care
- (TRICC ). University of Ottawa. $8500.
- Martin C. Assessment and development of criteria for intensive care unit admission from the emergency department
in teaching and non-teaching hospitals. Victoria Hospital Research Development Fund. $10000.
- Martin C. Dopexamine study. Porton Products Limited. $112330.
- Sibbald W, Martin C. Transfusing red blood cells stored in CPDA-1 for 21 days fails to restore tissue. Bayer/Canadian
Red Cross Society. $50000.
- Sibbald W, Inman K. A proposal to develop a multi-centre randomized trial evaluating the efficacy and cost-effectiveness
of tonometrically guided therapy in the critically ill. Tonometrics Inc. $71875 US.
- Sibbald W, Inman K. Preventing pressure ulcers in the critically ill: A randomized utilizing trial of low air
loss beds versus a support/relief program a variety of mattress overlays. GayMar Industries. $57291 US.
- Sibbald W. A randomized controlled trial of pentaspan versus 5% cardiopulmonary bypass in patients undergoing
coronary artery bypass. Dupont Pharma. $82966.
- Sibbald W, Myers ML. Myocardial delivery sepsis. Heart and Stroke Foundation of Ontario $46090.
- Sibbald W. Southwestern Ontario critical care research network (SOCCR Network). Richard & Jean Ivey Fund.
$50025.
- Sibbald W. The incidence of non-heart-beating-cadaver donors in the Southwestern Ontario critical care registry
(SOCCR). University Hospital Foundation. $10000.
- Sibbald W. A structured literature review on research transfer. Ontario Health Care Evaluation Network. $17258.
- Sibbald W. Current practices in ventilatory care in hospital intensive care. Organon Canada Ltd. $5000.
- Sibbald W. An evidence-based literature review on the use of sedatives in the intensive care unit. Zeneca Pharma
Inc. $6000.
- Sibbald W. Economic evaluation of kinetic therapy in the prevention of lower respiratory tract infections.
Kinetic Concepts Inc. $8433.
- Sibbald W, Doig, G. Anti-endotoxin therapy in an ovine model of hyperdynamic normotensive sepsis (Animal Study).
Sandoz Pharmaceuticals Corp. (US). $37360.
- Sibbald W, Doig, G. Polymyxin-dextran anti-endotoxin therapy in an ovine model of normotensive sepsis - Pilot
and Option 1. Sandoz Pharmaceuticals Corp. (US). $224972.
- Sibbald W. Physiological effects of a preclinical program to study the effects of RSR13 on the microcirculation
of RSR compounds coronary arteries. Allos Therapeutics Inc. $67887.
- Young B, Doig G, Rutledge F, An assessment of continuous EEG monitoring in the general intensive care unit.
Victoria Hospital Research Development Fund. $11000.
ENDOCRINOLOGY
The grants received by department/division members are listed as follows: the members of the division in bold
type, the title of the project, the sponsor, and the $'s expended at the London Health Sciences Centre in the fiscal
period.
- Canny C, Dupre J, Hramiak I. Tolrestat in the prevention of diabetic retinopathy. Wyeth- Ayerst. $116723.
- Chiasson J, McManus R, Rodger N. Prevention of diabetes Type II study. Bayer Inc. $5043.
- Chiasson J, McManus R, Rodger N. Miglitol/metformin study in NIDDM. Bayer Inc. $121286.
- Dupre J, Behme M, Hramiak I, McDonald T. Studies on the effect of GLP-1 of glycemic responses to meals in IDDM.
Amylin Pharmaceuticals. $130000.
- Dupre J, Hramiak I. A study to evaluate the effects of pramlintide (AC137) on glycemic control as determined
by glycated hemoglobin in patients with type I diabetes mellitus. Amylin Pharmaceuticals. $35000.
- Dupre J. Epidemiology of diabetes intervention and complications trial (EDIC). National Institutes of Health.
$102000.
- Dupre J, Hramiak I, Feldman R, McManus R. Studies on the effects of gliclazide on glucose tolerance and insulin
sensitivity. Servier-Canada. $50000.
- Dupre J, Atkinson P, Hramiak I, Behme M, Zucker P. Insulin sensitivity and glucose turnover in Islet-transplanted
diabetic rats. Canadian Diabetes Association. $60000.
- Dupre J, Rodger N. Diabetes control and complication trial. National Institute of Health. $87274.
- Dupre J, Zucker P, Hramiak I. Functions of syngeneic rat pancreas islets engrafted in hepatic, hepatic omental,
renal subcapsular sites. Departmental Funds. $4630.
- Dupre J, Mahon J. Clinical trial of nicotinamide in prevention of insulin-dependent diabetes mellitus (CANENDIT).
Medical Research Council of Canada. $97135.
- Dupre J, Mahon J. Screening and prevention of insulin-dependent diabetes mellitus. Medical Research Council.
$35000.
- Field L, Dupre J, Mahon J, Delovitch T, Singh B. Genetics of human diabetic autoimmunity, molecular mechanisms
of the development of insulitis, and its regulation in insulin-dependent diabetes millitus. Medical Research Council
of Canada/JDFI Centre Grant. $52000.
- Edmonds M, Browman G. Clinical data and home monitoring module. National Centres of Excellence - Information-based
decision tools in health care. Medical Research Council of Canada $32337 and SSHRC $32060.
- Edmonds M. Informatics theme - clinical data module chronic ambulatory care information systems: diabetes mellitus.
Network of Centres of Excellence. $5063.
- Edmonds M. Clinical theme - clinical data module chronic ambulatory care information system: diabetes mellitus.
Network of Centres of Excellence. $14963.
- Feldman R, Hramiak I. Beta-adrenal receptor regulation in man: alterations with hypertension, aging and dietary
salt restriction. Heart and Stroke Foundation. $66197.
- Hill D, Mc Donald T, Dupre J. Maintenance and Beta-cell survival by Islet growth and differentiation factors.
MRC/JDF Grant. $114000.
- Hramiak I, McDonald T. A multicentre efficacy and safety comparison of the human insulin analogue X-14 in Type
I diabetes mellitus. Novo Nordisk. $72000.
- Hramiak I, Dupre J. A multicentre study of ALCAR in the prevention of progression and treatment of diabetic
peripheral neuropathy. Hoffman-LaRoche. $258450.
- Hramiak I. Insulin lispro in the treatment of patients with Type II diabetes after oral agent failure. Eli
Lilly. $39950.
- Hramiak I, Dupre J. Free mixtures of insulin lispro protamine suspension (NPL) and insulin lispro in the treatment
of diabetes. Eli Lilly. $12500.
- Huff M. Regulation of lipoprotein metabolism. Heart and Stroke Foundation of Ontario. $101644.
- Huff M. Metabolism of apolipoproteins B,C, and E in man. Medical Research Council of Canada. $64484.
- Huff M. Apolipoprotein B metabolism. Heart and Stroke Foundation of Ontario. $112661.
- Huff M. Effect of atorvastatin on Apo B kinetic studies in miniature pigs. Parke-Davis Pharmaceutical Research.
$82182.
- Huff M. Effect of ACAT inhibitor on hepatic lipoprotein metabolism. Dupont-Merck Pharmaceuticals. $6980.
- Huff M. Effect of atorvastatin on hepatic lipoprotein metabolism. Parke-Davis. $41000.
- Huff M. Comparison of atorvastatin and simvastatin on hepatic Apo B secretion. Parke-Davis. $66484.
- Huff M. Effects of valsartin on plasma lipids and lipoproteins in patients with diabetic nephropathy. Ciba-Geigy.
$78134.
- Huff M. Prevention of diabetes Type II study STOP-NIDDM. Bayer Inc. $5043.
- Josse R, Rodger N, McManus R. Prandase in the treatment of elderly patients with NIDDM/Bayer Inc. $46800.
- McDonald T. Studies on GRP's role in pregnancy. LHSC Internal Research Fund. $15000.
- McDonald T. Regulatory peptides. Medical Research Council of Canada. $46742.
- McDonald T. Neuropeptide gastro-intestinal. Medical Research Council of Canada. $79678.
- McDonald T, Daniel E. Neuropeptide mechanisms of control of gastro-intestinal function. Medical Research Council
of Canada. $83872.
- McManus R. Effects of lactation on insulin sensitivity and visceral fat in women with a history of gestational
diabetes. Physician's Services Inc. Foundation. $35000.
- Roger NW, McManus R. Pramlintide on glyemic control in Type II diabetes mellitus. Amylin Pharmaceuticals. $16000.
- Wolfe B. Studies of the mechanisms of action of sex hormones upon lipoprotein metabolism in post-menopausal
women. Heart and Stroke Foundation. $70602.
- Wolfe B. Apolipoprotein secretion in liver. Bristol Myers Squibb. $6000.
- Wolfe B. Cholesterol and triglyceride metabolism. Heart and Stroke Foundation of Ontario. $6552.
- Wolfe B. Heart outcomes prevention evaluation (HOPE) study. University Hospital Foundation. $1150.
- Wolfe B. The effect of irbesartin on morbidity and mortality in hypertensive patients with Type II diabetes
and diabetic nephropathy. Bristol-Myers Squibb Pharmaceutical Research. $3000.
- Yusef S, Hramiak I, McManus R, Wolfe B. Multicentre HOPE study. Medical Research Council/Hoechst Rousell. $7150.
GASTROENTEROLOGY
The grants received by department/division members are listed as follows: the members of the division in bold
type, the title of the project, the sponsor, and the $'s expended at the London Health Sciences Centre in the fiscal
period.
- Adams P. Localization of the hemochromatosis gene. Detweiler Fellowship RCPSC. $10500.
- Adams P. Localization of the hemochromatosis gene. Medical Research Council of Canada- International Scientific
Exchange Award. $11000.
- Adams P, Ghent C. A pilot study to assess the safety and efficacy of lamivudine during the course of liver
transplantation for patients with chronic hepatitis B infection. Glaxo Wellcome Inc. $23540.
- Ghent CN. Interferon Hepatitis C. Schering Canada Inc. $24066.
- Gregor J, Feagan B. Utility measurements in chronically active Crohn's Disease. Schering- Plough. $38000.
- Gregor J. Department of medicine emergency referral pattern survey utility measurements in chronically active
inflammatory bowel disease. Victoria Hospital Department Funds. $40849.
- Howard J. Healing and prevention of NSAID induced gastroduodenal lesions. Astra Pharma Inc. $105.
- Howard J. Eradication of helicobacter pylori and ulcer healing in du patients with omeprazole in combination
with clarithromycin plus either amoxicillin or metronidazole. Astra Pharma Inc. $5300.
- McDonald J. Canadian Cochrane network. Medical Research Council of Canada. $2496.
- McDonald J. Grant for handsearching AGA abstracts for RCT's and CCT's for Cochrane Database. Janssen/Ortho
McNeil. $11000.
- McDonald J, Feagan B. Methotrexate in chronically active Crohn's Disease. Medical Research Council. $170586.
- McDonald J, Feagan B. Inflammatory bowel disease research and the Cochrane collaboration. Collip. J. B. Research
Fund. $1105.
- McDonald J, Rochon J, Feagan B. North American Crohn's study group. Medical Research Council. $194052.
- McDonald J. Crohn's study group - Mtx trial. University Chicago Hospitals. $49553.
- McDonald J. 3M clinical trials. HGO Medical Associates. $10000.
- McDonald J. Medicine North America. CME Publishing Ltd. $2000.
- McDonald J. American Crohn's study group. Crohn's and Colitis Foundation. $10845.
GENERAL INTERNAL MEDICINE
The grants received by department/division members are listed as follows: the members of the division in bold
type, the title of the project, the sponsor, and the $'s expended at the London Health Sciences Centre in the fiscal
period.
- Feagan B. A comparative study of the efficacy and safety of budesonide enema versus betamehasone enema in active
ulcerative colitis. Astra Pharma Inc. $18240.
- Feagan B. Canadian orthopaedic perioperative erythropoietin study II (COPES II). Jansen-Ortho. $500000.
- Feagan B. Utility measurements in inflammatory bowel disease. Schering Plough. $38000.
- Feagan B IL-10 in chronic active Crohn's disease. Schering Plough. $74680.
- Feagan B. Cyclosporine for treatment of severe exacerbations of ulcerative Colitis. Crohn's and Colitis Foundation
of Canada. $25000.
- Feagan B, McDonald J. Prednisone maintenance therapy for Crohn's Disease. University of Toronto. $3000.
- Feagan B. The North American Crohn's study group: evaluation of (4/95 - 3/96) methotrexate. Medical Research
Council of Canada. $47301
- Feagan B. The North American Crohn's study group: evaluation of methotrexate. Crohn's and Colitis Foundation
of Canada. $29535.
- Feagan B. A comparison of patient directed management of chronic hypertension with office based management:
a pilot project. University Hospital Pooled Research Trust Fund and Miles Canada. $24000.
- Feagan B. Prednisone maintenance therapy for Crohn's Disease. Medical Research Council of Canada. $163455.
- Feagan B, Fedorak R, Steinhart J. A randomized trial of cyclosporine in acute ulcerative colitis. Crohn's and
Colitis Foundation of Canada. $39380.
- Mahon J. The efficacy and cost-effectiveness of N of 1 trials. Ontario Ministry of Health. $44271.
- Mahon J. A randomized controlled trial of active compression-depression versus standard cardiopulmonary resuscitation
for cardiac arrest. Ontario Ministry of Health. $45000.
- Mahon J, Dupre J. Screening and prevention for insulin dependent diabetes mellitus. Medical Research Council.
$198643.
- Mahon J, Pope J. The efficacy and cost-effectiveness of N of 1 studies compared to standard treatment with
NSAIDs in osteoarthritis. Physicians' Services Inc. Foundation. $80000 and $26667.
- Mahon J. The cost and consequences of awaiting elective total hip replacement. Physicians' Services Inc. Foundation.
$33300.
- Mahon J. Propranolol for small abdominal aortic aneurysms. Medical Research Council of Canada. $16000.
- Mahon J. Propranolol trial. Ottawa Civic Hospital. $7800.
- Mahon J. Elective total hip replacement. Physicians' Services Inc. Foundation. $1500.
- Roach M. Fibrous atherosclerosis. Heart and Stroke Foundation. $65932.
- Roach M. Aortic dissections. Medical Research Council of Canada. $22158.
- Roach M, Fenster A, Sherebrin M. Angioplasty and arterial elasticity. Heart and Stroke Foundation of Ontario.
$50382.
- Roach M. Dissecting aneurysms. Medical Research Council of Canada. $44316.
- Roach M. Atherosclerosis. Royal Arch Masons - Release a Miracle Fund. $4000.
INFECTIOUS DISEASES
The grants received by department/division members are listed as follows: the members of the division in bold
type, the title of the project, the sponsor, and the $'s expended at the London Health Sciences Centre in the fiscal
period.
- Austin T, Melendez L. Multicentre aspirin trial in infective endocarditis. Heart & Stroke Foundation. $1400.
- Ralph E, John M. Pharmacoeconomic assessment of cefapime in hospitals. Bristol-Myers Squibb. $2000.
NEPHROLOGY
The grants received by departmental/division members are listed as follows: the members of the division in bold
type, the title of the project, the sponsor, and the $'s expended at the London Health Sciences Centre in the fiscal
period.
- Blake P. Acute effects of amino acids and of their route of administration on hormonal mediators of anabolism
and catabolism in CAPD patients. Physicians' Services Inc. Foundation. $58000.
- Blake P. What is the optimal APD prescription? Baxter Canada. $15000.
- Blake P. Compare local tolerability of subcutaneous injections of epoetin alpha with citrate buffer and epoetin
with phosphate buffer. Ortho Biotech. $6000.
- Blake P, Lindsay R, Clark W, Kortas C. Investigation of hemodia-filtration therapy and investigation clinical
applications of non-invasive BVM. Hospal-Gambro Inc. $60000.
- Blake P. Verification of performance data on the Focus series of hemodialyzers. National Medical Care. $17000.
- Clark W. Flaxseed in lupus nephritis: a prospective, randomized, crossover study. Departmental Research Funds.
$18699.
- Clark W. Flaxseed in diabetic nephropathy - a dosing study. Departmental Research Funds. $8773.
- Clark W. Plasma exchange in the treatment of HUS/TTP due to E.coli 0157:H7: a novel approach. Departmental
Research Funds. $2522.
- Clark W. SDG-lignans in experimental lupus nephritis. The Kidney Foundation of Canada. $29855.
- Jevnikar A. Modulation of lupus nephritis in MRL mice by FAS, FAS ligand. Medical Research Council. $71356.
- Jevnikar A, Singh B. Autoimmunity and Islet transplantation in MHC deficient NOD mice. Medical Research Council
of Canada. $30715.
- Jevnikar A. Expression of major histocompatibility complex Class II and biologically active molecules in transgenic
tobacco and other plants. Departmental Research Funds. $6700.
- Jevnikar A. Biorad Gs-525 molecular imager PC system (Phosphoimager). University Hospital Pooled ResearchTrust.
$3000.
- Jevnikar A. Expression of major histocompatibility complex Class II and autoantigens in plants. MOTS Research
Program. $51617.
- Jevnikar A. Role of renal MHC Class II molecule & TGFß expression in autoimmune nephritis. Medical
Research Council of Canada. $58837.
- Jevnikar M, Ma S. Oral tolerance to major histocompatibility complex (MHC) Class II proteins in autoimmune
nephritis and transplant rejection. The Kidney Foundation of Canada. $33000.
- Jevnikar T. Development of HLA-DRA-1E Class II transgenic, murine Class II deficient MRL-1pr mice. LHSC Internal
Research Fund. $14000.
- Kortas C. Flaxseed in hemodialysis: effects on atherogenic risk factors. Physicians' Services Inc. Foundation.
$33000.
- Lazarovits A. NEORAL conversion study, clinical trial. Sandoz Canada Ltd. $9225.
- Lazarovits A. Integrin signals via tyrosine. Crohn's and Colitis Foundation of Canada. $59845.
- Lazarovits A. CD7 associated with CD3 & CD45. Kidney Foundation Canada. $40000.
- Lazarovits A. CD45rb monoclonal antibody for prevention of transplant rejection. Departmental Research Funds.
$8000.
- Lazarovits A. CD7 is associated with CD28 & phosphoinositide 3-kinase on human T cells. Departmental Research
Funds. $3602.
- Lazarovits A. Prevention, reversal of rejection and induction of tolerance by MAB to Cd45rb in monkey kidney
transplantation model. MOTS Research Program. $40378.
- Lazarovits A. CD7 is associated with CD28 and phosphoinositide 3-kinase on human T cells. The Kidney Foundation
of Canada. $40000.
- Lazarovits A, Zhong R. Prevention, reversal of rejection and induction of tolerance by MAB to CD45RB . The
Physicians' Services Inc. Foundation. $70000.
- Lazarovits A. A study of the treatment of acute renal graft rejection. Bristol-Myers Squibb. $5126.
- Lazarovits A. FACS core facility. Multi-Organ Transplant Service. $30000.
- Lazarovits A. CHI-621 Study: a trial for prevention of acute cellular rejection. Sandoz Canada Inc. $30628.
- Lazarovits A. HAT Study: a trial of humanized anti-TAC with standard two drug immunosuppressive therapy for
prevention of acute allograft rejection in recipients of first cadaver renal transplants. Hoffman-LaRoche Limited.
$40245.
- Lazarovits A. CD7 Study: Open and randomized phase II trials of human-mouse chimeric monoclonal antibody CHH380
(CD7). Sandoz Canada Inc. $70392.
- Lazarovits A, Madrenas O, Ochi A. Regulation of T cell signal transduction in insulitis and diabetes. Medical
Research Council of Canada/Junior Diabetes Foundation International. Diabetes Research. $37000.
- Lindsay R, Nissenson A. Comparative randomized safety and efficacy study of Ferrlecit end-stage renal disease
on long-term haemodialysis. R&D Laboratories Marina del Rey, California. $132500.
- Lindsay R. An evaluation of the HG600 dialyser. GAMBRO Healthcare Corporation, Denver. Colorado. $4260.
- Lindsay R. Comparison of methods for the measurement of access recirculation and blood flows. GAMBRO Healthcare
Corporation, Denver, Colorado. $23500.
- Lindsay R. Evaluation of a haematocrit dilution technique to monitor blood volume during dialysis. In-Line
Diagnostics Incorporated, Riverdale, Utah. $40000.[equipment grant].
- Lindsay R. Adequacy of haemodialysis. COBE Canada, Scarborough. Ontario. $10000.
- Lindsay R. Dialysis Studies. Departmental Funds. $25319.
- Lindsay R. Dialysis Studies. COBE Canada. $23200.
- Muirhead N, Hollomby D, Stiller C. A pharmaco-epidemiologic study to compare the pharmacokinetic, safety, therapeutic,
clinical and economic benefits of sandimmune neoral to sandimmune. Sandoz. $200000.
- Muirhead N, Stiller C. A single-blind pilot study of the effects of oral rapamycin on the occurrence of acute
rejection episodes in renal allograft recipients. Wyeth-Ayerst. $88000.
- Muirhead N, Feagan B, Mahon J. A study of Valsartan and Captopril on urinary albumin excretion, renal function
and plasma lipid profile, in normotensive patients with Type II diabetes mellitus and nephropathy. Ciba-Geigy Canada
Ltd. $90000.
- Muirhead N. A trial to assess the effect of normalization of hemoglobin using epoetin, on cardiomyopathy in
hemodialysis patients without symptomatic cardiac disease. Ortho Pharmaceuticals Ltd. $84000.
- Muirhead N. A clinical trial to evaluate the safety and efficacy of auriculin anaritide in the treatment of
oliguric acute tubular necrosis. Scios Inc. $65500.
- Muirhead N, Wolfe B. The effect of irbesartan on morbidity and mortality in hypertensive patients with Type
II diabetes and diabetic nephropathy. Bristol Myers Squibb. $70000.
- Muirhead N. A European multicentre randomized controlled study of the long term effects of Fluvastatin (LESCOL)
on major adverse cardiac event (MACE)and progression of chronic transplant dysfunction in renal transplanted patients.
Sandoz. $33333.
- Parbtani A. Comparative efficacy low protein study on kidney patients. Departmental Funds. $57568.
- Stiller C. Rapamycin Study: A study of the safety and tolerance of orally administered rapamycin. Wyeth-Ayerst
Canada Inc. $22371.
- Stiller C. NOF-9 Study: A pharmacoepidemiologic study to compare the pharmacokinetic, safety, therapeutic,
clinical and economic benefits of Sandimmune Neoral to Sandimmune. Sandoz Canada Inc. $135517.
- Stiller C. RS023X Study: A multicentre comparative study of drugs for management of renal allograft recipients
immediately post-transplant for prevention of rejection. Syntex Hoffman- LaRoche Limited. $17683.
RESPIROLOGY
The grants received by department/division members are listed as follows: the members of the division in bold type,
the title of the project, the sponsor, and the $'s expended at the London Health Sciences Centre in the fiscal
period.
- Ferguson K. Upper airway imaging and oral appliances in the treatment of obstructive sleep apnea. Physicians'
Services Inc. Foundation. $56500.
- Ferguson K. Pilot study of upper airway imaging and oral appliances in patients with obstructive sleep apnea.
University Hospital Pooled Research Trust Fund. $6696.
- Ferguson K. Pilot study of laser assisted uvulopalatoplasty in the treatment of mild obstructive sleep apnea.
Ontario Thoracic Society. $7400.
- Ferguson K. Pilot study of the effects of oral appliances on the upper airway in patients with obstructive
sleep apnea. Ontario Thoracic Society. $6500.
- Ferguson K. Pilot study of laser assisted uvulopalatoplasty in the treatment of mild obstructive sleep apnea.
University Hospital Pooled Research Trust Fund. $4623.
- Ferguson K. Upper airway imaging and oral appliances in the treatment of obstructive sleep apnea. University
Hospital Pooled Research Trust Fund. $6896.
- Ferguson K. Pilot study of upper airway imaging and oral appliances in patients with obstructive sleep apnea.
Departmental Funds. $6696. .
- George C. Randomized double-blind placebo controlled crossover safety and efficacy study of zaleplon. Wyeth
Ayerst Research. $70322.
- George C. A controlled trial of modafinil in the treatment of excessive daytime sleepiness in narcoleptics.
Draxix Health Inc. $50807.
- George C. Assessment of driving performance and its relationship to sleepiness and degree of severity in disorders
of excessive daytime somnolence. Medical Research Council of Canada. $38808.
- Leasa D, Malthaner R. Pilot study: lung volume reduction surgery in emphysema. Ontario Thoracic Society. $7500.
- Leasa D, Cook D. Randomized trial of stress, ulcer prophylaxis with sucralfate vs ranitidine - effect on nosocomial
pneumonia. Medical Research Council of Canada\ Nordic Merrell Dow Research Inc. $40000.
- Leasa D. Levels of care for critically ill patients: a multicentre observational study. LHSC Internal Research
Fund. $10000.
- McCormack D, Lewis J. Interaction between inhaled nitric oxide therapy and surfactant administration in acute
lung injury . Ontario Thoracic Society. $6500.
- McCormack D, Lewis J. Nitric oxide and abnormal vascular reactivity in pneumonia. Ontario Thoracic Society
. $23300.
- McCormack D. Interactions between nitric oxide and hyperoxia. Ontario Thoracic Society. $7500.
- McCormack D. Multi-centre study evaluating the role of fluticasone and salmeterol in the management of chronic
asthma. Glaxo. $12000.
- McCormack D. Evaluation of a new delivery device for ipratropium bromide in patients with asthma and COPD.
Boehringer/Ingelheim. $60000.
- McCormack D. Efficacy and safety of nebulization therapy in acute asthma. Boehringer Ingelheim Ltd. $92760.
- McCormack D. A phase III study of R - Methug - Csf in the treatment of severe community acquired pneumonia.
Amgen Canada. $22800.
- Paterson N, Hartford K, Mahon J, Speechley M. Prevalence and treatment of asthma in Southwestern Ontario. LHSC
Victoria Campus Department of Medicine. $15000.
RHEUMATOLOGY
The grants received by departmental/division members are listed as follows: the members of the division in bold
type, the title of the project, the sponsor, and the $'s expended at the London Health Sciences Centre in the fiscal
period.
- Bell D. Induction and regulation of B lymphocyte proliferation by nucleosomes. The Arthritis Society. $60000.
- Bell D. Rheumatic Diseases Unit - University Hospital. The Arthritis Society. $13750.
- Bell D. The role of HLA DR4B and viral peptides in pathogenesis or rheumatoid arthritis. LHSC Internal Research
Fund. $6000.
- Bellamy N. Rheumatic disease unit - Victoria Campus. The Arthritis Society. $8000.
- Bellamy N. A multicentre, controlled group trial of arthrotec versus acetaminophen with osteoarthritis of the
knee. Searle Canada. $180000.
- Bellamy N. A multicentre comparative study of generic health status measures in osteoarthritis of the knee.
Searle Canada. $120000.
- Bellamy N. Arthrotec vs acetaminophen vs placebo clinical trial. Medical Research Council of Canada. $11471.
- Bellamy N. Tenidap in rheumatoid arthritis collaborative international study (Tracis). Pfizer Canada. $50936.
- Bellamy N. Development of a disability index for outcome assessment in osteoarthritis hand clinical trials.
Pfizer, U.S.A. $6850.
- Bellamy N. An evaluation of the analgesic efficacy equivalence of tramadol hydrochloride and ibuprofen in subjects
with chronic pain of osteoarthritis. Ortho-McNeil Inc. $16852.
- Bellamy N. Tenidap in rheumatoid arthritis collaborative international study (TRACIS). Pfizer Canada Inc. $88400.
- Cairns E, Bell A. Structure anti-antibodies. The Arthritis Society. $57600.
- Cairns E. Immunotoxin for anti-antibody B cells. Departmental Funds. $9703.
- Cairns E. Mutation in the regulatory ec-receptor and clinical autoimmunity. LHSC Internal Research Fund. $12500.
- Harth M, McKendry R, Esdaile J,Thompson J. Maintenance gold, discontinuation study. The Arthritis Society.
$34000.
- Hodsman A, Pope J, Harth M. A study, to determine the safety and efficacy of intermittent cyclical therapy
etidronate in the prevention of corticosteroid-induced osteoporosis (CIOP) . Procter and Gamble, Canada. $46984
- Pope J, Mahon J. A randomized controlled trial of N of 1 treatment in osteoarthritis compared to standard treatment:
a cost analysis. Physicians' Services Inc. Foundation. $40000.
- Pope J. Do certain NSAIDS provide chondro-protection in osteoarthritis of the hip and knee? A preliminary study.
Victoria Hospital Research Development Fund. $13000.
- Pope J. Increased pigmentation in scleroderma. Ontario Scleroderma Foundation. $8800.
- Pope J. Methotrexate in scleroderma. Physicians' Services Inc. Foundation. $20000.
- Pope J. Variability scleroderma. Departmental Funds. $16483.
- Pope J. Does active SLE without renal disease cause hypertension? An investigation of the vascular integrity
of lupus patients. Victoria Hospital Department of Medicine Research Fund. $15000.
- Pope J. A randomized placebo controlled trial of estrogen in postmenopausal women with SLE. Ontario Lupus Association.
$15000.
- Pope. J. A randomized placebo controlled trial of estrogen in postmenopausal women with SLE. Victoria Hospital
Department of Medicine Research Fund. $40000.
- White K, Speechley M, Ostbye T, Harth M. London fibromyalgia epidemiology study. National Health Research Development
Program. $24973.
- White K, Speechley M, Ostbye T, Harth M. London fibromyalgia epidemiology study. The Arthritis Society. $8167.
- White K, Speechley M, Ostbye T, Harth M, Nielson W. London fibromyalgia epidemiology study (Phase IV). The
Arthritis Society. $16395.
